Research Progress in Alzheimer's Disease & Dementia
Nova Science Publishers Inc (Verlag)
978-1-59454-949-6 (ISBN)
Alzheimer's disease (AD) is the most common type of neurodegenerative disorder in the ageing population, with dementia as a common consequence. AD is defined pathologically by the appearance of extracellular senile plaques and intracellular neurofibrillary tangles, as described by Alois Alzheimer about a century ago. The causes for AD include genetic predisposition in a small population, ageing and environmental stresses in majority cases. The underlying pathogenic cascades, increases in expression of amyloid precursor protein and accumulation of Ass and reactive oxidant activity and inflammation, have the features of both adaptive, at least initially, and harmful when becoming excessive. Dementia, on the other hand, is a clinical diagnosis and is defined as globally, persistently impaired cognitive skills including memory. Alzheimer dementia refers to clinical dementia in patients who also have Alzheimer neuropathology. Alzheimer dementia is what brings the patients to seek medical treatments. An extraordinary inability to form new memory, especially of those episodic type, and executive dysfunction are among the earliest symptoms in AD patients. In end-stage AD, cognitive degeneration extends far beyond memory loss. The underlying causes include decreases in impaired brain metabolism, which results in impaired synaptic functions and capacities, thus impaired information processing, and eventually leads to neuronal injury and death. This book presents leading-edge research in this dynamic field.
Miao-Kun Sun, Ph.D. obtained his Ph.D. at the Department of Pharmacology, University of Virginia, in 1986, and continued postdoctoral research at the same department for two more years. After a brief research period (one year) at the Department of Physiology, Royal Free Hospital School of Medicine, University College of London, he accepted a faculty position at Department of Neurology and Neuroscience, Cornell University Medical College in New York in 1990. His current position is Professor at Blanchette Rockefeller Neurosciences Institute (holding the same position since 2000).
Preface; Neuroimaging in Alzheimers Disease and Mild Cognitive Impairment; Executive Dysfunction in Alzheimers Disease; Alzheimers Disease Therapies: Updates on Genetic and Pharmacological Manipulations of ss-Secretase; Neuronal Deregulation of Tau Phosphorylation: Implications for Mechanisms and Treatment of Alzheimer's Disease; Immunotherapeutic approach in Alzheimer's disease; Immunotherapy for Alzheimers Disease and Dementia; Ass-degrading Enzyme, Eprilysin; Memantine as an Antidementic Drug; Neurogenesis and Alzheimers Disease; Glyoxalase I and its Role in Human Disease; Brain insulin Function and Insulin Signal Transduction in Sporadic Alzheimer Disease; Apolipoprotein E and Cerebral Amyloid Angiopathy in Alzheimers Disease; Limbic Metabolic Changes and Alzheimers Disease; Oxidative Damage is the Earliest Change of Alzheimer Disease: Therapeutic Opportunities; Chronic Antioxidant Treatments and Memory in a Transgenic Mouse Model of Alzheimers Disease; Drosophila as a Model for Studying Disease Mechanisms of Alzheimers and Related Dementia; Androgens, ApoE, and Alzheimers Disease; Pivotal Roles of Cholesterol and Gangliosides in Aggregation of Amyloid ss-protein; Imaging Cerebral Atrophy in Alzheimers Disease; Index.
Erscheint lt. Verlag | 2.7.2007 |
---|---|
Zusatzinfo | Illustrations |
Verlagsort | New York |
Sprache | englisch |
Maße | 260 x 180 mm |
Gewicht | 1152 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Geriatrie |
ISBN-10 | 1-59454-949-4 / 1594549494 |
ISBN-13 | 978-1-59454-949-6 / 9781594549496 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich